Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early hydrocortisone to prevent bronchopulmonary dysplasia in premature neonates
IRCT20120215009014N557Phase 3Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in bronchopulmonary dysplasia (BPD) comparing Hydrocortisone early initiation with Placebo (2 arms). Primary endpoint: Prevention of bronchopulmonary dysplasia. Started May 2025; status: completed.
02
Drugs
hydrocortisone
03
Conditions
bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on IRCT20120215009014N557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20120215009014N557.